Tandem Diabetes Care Inc (NASDAQ:TNDM)’s share price was down 13.3% during mid-day trading on Tuesday . The stock traded as low as $2.76 and last traded at $2.81. Approximately 1,100,163 shares traded hands during trading, a decline of 12% from the average daily volume of 1,247,796 shares. The stock had previously closed at $3.24.

Several equities analysts have issued reports on TNDM shares. Zacks Investment Research upgraded shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a research note on Wednesday, November 1st. Wedbush reiterated an “outperform” rating and issued a $17.00 price objective (down previously from $50.00) on shares of Tandem Diabetes Care in a research note on Tuesday, October 10th. Piper Jaffray Companies reiterated a “hold” rating and issued a $15.00 price objective on shares of Tandem Diabetes Care in a research note on Friday, October 6th. Finally, Robert W. Baird reiterated a “hold” rating and issued a $3.00 price objective on shares of Tandem Diabetes Care in a research note on Sunday, November 19th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Tandem Diabetes Care currently has a consensus rating of “Hold” and a consensus price target of $11.29.

The company has a debt-to-equity ratio of -2.70, a current ratio of 1.90 and a quick ratio of 0.88. The firm has a market cap of $28.43, a P/E ratio of -0.14 and a beta of 0.17.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings data on Thursday, October 26th. The medical device company reported ($3.09) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($3.74) by $0.65. The business had revenue of $27.00 million during the quarter, compared to the consensus estimate of $25.92 million. During the same quarter last year, the company earned ($0.97) EPS. Tandem Diabetes Care’s revenue for the quarter was up 119.7% on a year-over-year basis. equities analysts expect that Tandem Diabetes Care Inc will post -15.37 earnings per share for the current year.

Several large investors have recently modified their holdings of TNDM. Wedbush Securities Inc. lifted its stake in shares of Tandem Diabetes Care by 88.6% in the 3rd quarter. Wedbush Securities Inc. now owns 188,877 shares of the medical device company’s stock worth $138,000 after purchasing an additional 88,709 shares during the period. Russell Investments Group Ltd. increased its holdings in Tandem Diabetes Care by 93.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 581,245 shares of the medical device company’s stock worth $465,000 after acquiring an additional 280,551 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in Tandem Diabetes Care by 2.7% in the 2nd quarter. Vanguard Group Inc. now owns 1,233,607 shares of the medical device company’s stock worth $987,000 after acquiring an additional 32,991 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.dailypolitical.com/2018/01/17/tandem-diabetes-care-tndm-shares-down-13-3.html.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.